Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several tens of millions of RMB. This round was led by Hangzhou Lingxin, with existing shareholder Mifang Health Fund participating. With this financing, Med Vision has cumulatively raised over 100 million RMB in its Series A funding. The company plans to expedite the commercialization of multiple digital therapy products while enhancing its core technological capabilities.
Innovative Solutions for Mental Health Disorders
Founded in 2016, Med Vision focuses on the field of mental health disorders, developing a product pipeline addressing conditions such as depression, anxiety, sleep disorders, addiction, and child development. The company aims to provide a comprehensive virtual reality (VR) digital therapy (DTx) solution for society, positioning itself as a leader in this emerging sector.
Strategic Collaborations and Clinical Applications
Currently, Med Vision collaborates with numerous VR clinical application research centers and has established partnerships with key institutions, including the Zhejiang Provincial Mental Health Center and the Shanghai Mental Health Center. The company also works with several regional hospitals, including Huashan Hospital, Zhongshan Hospital, Renji Hospital, and the PLA 301 Hospital, to advance clinical applications of its technologies.
Discussing the investment rationale, Zhou Yujian, managing partner of Mifang Health Fund, stated, “Med Vision is among the first companies in China to engage in digital therapies. It has been a pioneer in VR digital therapy solutions for mental health, leading to the recognition of VR technology in this field by the NMPA. The company addresses core areas of mental health, such as insomnia, anxiety, and ADHD in children, presenting a vast market opportunity. Med Vision has attracted investments and business collaborations from leading companies in the pharmaceutical sector, laying a solid strategic foundation for product commercialization.”-Fineline Info & Tech
